Hungarian Brain Research Program((2017-1.2.1-NKP-2017-00002)
(K-129065)
(MSD Pharma Hungary)
Szakterületek:
Klinikai orvostan
Onkológia
Patológia
Objective: Lung cancer is one of the most common cancers worldwide and its survival
is still poor. The objective of our study was to estimate long-term survival of Hungarian
lung cancer patients at first time based on a nationwide review of the National Health
Insurance Fund database. Methods: Our retrospective, longitudinal study included patients
aged >= 20 years who were diagnosed with lung cancer (ICD-10 C34) between January
1, 2011 and December 31, 2016. Survival rates were evaluated by year of diagnosis,
patient gender and age, and morphology of lung cancer. Results: 41,854 newly diagnosed
lung cancer patients were recorded. Mean age at diagnosis varied between 64.7 and
65.9 years during study period. One- and 5-year overall survival rates for the total
population were 42.2 and 17.9%, respectively. Survival was statistically associated
with gender, age and type of lung cancer. Female patients (n = 16,362) had 23% better
survival (HR: 0.77, 95% confidence interval (CI): 0.75-0.79; p < 0.001) than males
(n = 25,492). The highest survival rates were found in the 20-49 age cohort (5Y =
31.3%) and if the cancer type was adenocarcinoma (5Y = 20.5%). We measured 5.3% improvement
(9.2% adjusted) in lung cancer survival comparing the period 2015-2016 to 2011-2012
(HR: 0.95 95% CI: 0.92-0.97; p = 0.003), the highest at females <60 year (0.86 (adjusted
HR was 0.79), interaction analysis was significant for age and histology types. Conclusion:
Our study provided long-term Lung cancer survival data in Hungary for the first time.
We found a 5.3% improvement in 5-year survival in 4 years. Women and young patients
had better survival. Survival rates were comparable to-and at the higher end of-rates
registered in other East-Central European countries (7.7%-15.7%).
